ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Tissue enhanced |
ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ABCC8 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABL1 | C-abl oncogene 1, non-receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADH1A | Alcohol dehydrogenase 1A (class I), alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
ADK | Adenosine kinase | Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ADORA2A | Adenosine A2a receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADORA2B | Adenosine A2b receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ADORA3 | Adenosine A3 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1B | Adrenoceptor alpha 1B | Cancer-related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1D | Adrenoceptor alpha 1D | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA2A | Adrenoceptor alpha 2A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ADRA2B | Adrenoceptor alpha 2B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB2 | Adrenoceptor beta 2, surface | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
ADRB3 | Adrenoceptor beta 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AKR1D1 | Aldo-keto reductase family 1, member D1 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
ALAD | Aminolevulinate dehydratase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ALDH2 | Aldehyde dehydrogenase 2 family (mitochondrial) | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
ALK | Anaplastic lymphoma receptor tyrosine kinase | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALOX5 | Arachidonate 5-lipoxygenase | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AMY2A | Amylase, alpha 2A (pancreatic) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Transporters
| | | | | Expressed in all |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
AR | Androgen receptor | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Transcription factors
| | | | | Tissue enhanced |
ASIC1 | Acid-sensing (proton-gated) ion channel 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP6V1B2 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 | FDA approved drug targets Transporters
| | | | | Expressed in all |
AVPR1A | Arginine vasopressin receptor 1A | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
AVPR1B | Arginine vasopressin receptor 1B | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Not detected |
AVPR2 | Arginine vasopressin receptor 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
BCHE | Butyrylcholinesterase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |